The U.S. Department of Transportation (DOT) is proposing a new rule that would set maximum travel speeds for heavy-duty vehicles. Set forth by the DOT’s National Highway Traffic Safety Administration (NHTSA) and Federal Motor Carrier Safety Administration (FMCSA), the new rule is expected to save lives and more than $1 billion in fuel annually.
Read Full Release
The 2016 New England Regional Innovation Summit is a two-day engagement opportunity being held at MIT, for technology innovators and entrepreneurs. This effort, spearheaded by the SBA Office of Investment and Innovation (OII), is a coordinated effort amongst participating SBIR/STTR agencies to continually engage, identify, and encourage participation in the SBIR/STTR programs. The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, affectionately referred as America’s Seed Fund, play an instrumental role in providing early stage, non-dilutive, research and development capital which spurs small advanced technology firms’ innovations. Annually more than $2.5 billion non-diluted in early stage research and development funding is provided through these programs.
Read Full Release
Following recent share performance that has shares almost doubling in the past two
weeks, we continue to see room for share appreciation as the Xtampza ER launch has
clear tailwinds as we exit the summer through 2017. Management has signed at least
one large managed care win with UnitedHealth (UNH $140.00) and we believe
additional managed care wins are likely during the fourth quarter as well as the
potential for comparative data between OxyContin and Xtampza ER being added to
label. Admittedly, the Xtampza ER launch was slow as management chose to launch
during the summer months despite the historically slow season, which was
compounded by a lack of approved marketing materials. However, the company
recently received approved marketing materials and given formulary wins (both
UnitedHealth and likely additional wins), we should see a ramping up of scripts over
the next quarter and into 2017.
Read Full Release
Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the publication of “Oral Human Abuse Potential of Oxycodone DETERx® (Xtampza® ER),” in the peer-reviewed medical journal, The Journal of Clinical Pharmacology.
The publication presents the results from a human abuse potential (HAP) study, which was designed to evaluate the abuse potential and pharmacokinetics of oral administration of intact Xtampza® ER (oxycodone extended-release), oral administration of chewed Xtampza ER, and oral administration of crushed immediate-release oxycodone in non-dependent, recreational drug abusers.
Read Full Release
Today’s financing environment for emerging biotech companies presents a number of challenges. Venture capital funds are ever more cautious about taking risk, and some players have departed the field at the early stage. Government grants have also closed their spigots in recent years, as the volume of government funding has plummeted dramatically. However, new players have entered the fray in the last few years, including family offices, super angels, strategic partners and foreign investors, replacing the investment dollars previously offered by institutional investors. So where does an emerging biotech company forage for precious dollars? Come join us on September 22nd at the CIC in Cambridge to hear a panel of experts discuss these trends. At the event, you will discover, among other ideas:
Where and how to find the new players;
What areas of interest are these players financing;
How to optimize your chances of success;
What are deal structures looking like?
Read Full Release
From early startups to growth-stage companies to highly successful businesses, the CED Tech Venture Conference reflects North Carolina’s vibrant entrepreneurial community and showcases many of the most-promising emerging companies in the region. Attendees will have the opportunity to connect with a diverse group of over 100 investors, from venture capital to corporate to angels, including funds such as Sequoia Capital, Greycroft, Grotech Ventures, and Comcast Ventures. Engage with industry leaders, radical thinkers and trail-blazing entrepreneurs, and learn about the disruptive innovations that are transforming the ways in which we live, work and play.
Read Full Release
Rich investors have been pouring more money into private equity to avoid a potential stock market downturn, according to a new report. Read more here: http://www.cnbc.com/2016/09/12/wealthy-investors-are-putting-more-money-into-private-equity.html
Read Full Release
Mandates for the provision of telemedicine have driven insurance companies and employers to jump into arrangements with many telemedicine companies.The availability of low-risk arrangements for the payer make these deals attractive because they’re light on out-of-pocket expenses, often only charging when a visit occurs or requiring a co-pay to discourage use. But offering care in a lower-cost venue only saves money if people use it.
Read Full Release
We are pleased to present the report of the Cancer Moonshot’s Blue Ribbon Panel. The report describes a set of consequential recommendations for accelerating cancer research to achieve the ambitious goal of making a decade’s worth of cancer research progress in five years and to bring the most promising science and clinical developments to cancer patients in the near term. Read more here: http://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/blue-ribbon-panel/blue-ribbon-panel-report-2016.pdf
Read Full Release
